$1.67 Billion is the total value of Frazier Life Sciences Management, L.P.'s 48 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | NABRIVA THERAPEUTICS PLC | $0 | – | -17,025 | -100.0% | -0.00% | – | |
| ALLK | Exit | ALLAKOS INC | $0 | – | -1,112,684 | -100.0% | -0.36% | – |
| Exit | ZYMEWORKS INC | $0 | – | -610,000 | -100.0% | -0.40% | – | |
| RNA | Exit | AVIDITY BIOSCIENCES INC | $0 | – | -500,000 | -100.0% | -0.56% | – |
| VECT | Exit | VECTIVBIO HLDG AG | $0 | – | -1,352,199 | -100.0% | -0.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRUM PHARMACEUTICALS INC | 10 | Q2 2024 | 13.6% |
| ARCUTIS BIOTHERAPEUTICS INC | 10 | Q2 2024 | 17.0% |
| KRYSTAL BIOTECH INC | 10 | Q2 2024 | 8.5% |
| PHATHOM PHARMACEUTICALS INC | 10 | Q2 2024 | 8.6% |
| VAXCYTE INC | 10 | Q2 2024 | 4.8% |
| TARSUS PHARMACEUTICALS INC | 10 | Q2 2024 | 2.7% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2024 | 2.4% |
| ANAPTYSBIO INC | 10 | Q2 2024 | 2.5% |
| COGENT BIOSCIENCES INC | 10 | Q2 2024 | 2.4% |
| MERUS N V | 10 | Q2 2024 | 1.4% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-15 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.